1. Market Research
  2. > Stallergenes SAS (GENP) - Financial and Strategic SWOT Analysis Review

Stallergenes SAS (GENP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Stallergenes SAS (Stallergenes), a subsidiary of Stallergenes Greer is a biopharmaceutical company, which provides treatments for allergy-related respiratory diseases. The company develops diagnostic tests and products with principal focus on allergies. The company offers treatment for important respiratory diseases, which include severe rhino conjunctivitis and rhinitis, and allergic asthma. Stallergenes provides allergen immunotherapy in various dosage forms including injectable or subcutaneous injections, liquid sublinguals and solid sublinguals. Its research and development activities involve development of candidate products, laboratory research, clinical development and regulatory activities. The company distributes its products to various countries in North America, Europe, Africa; Asia and in Australia. Stallergenes is headquartered in Antony, France.

Stallergenes SAS Key Recent Developments

Feb 10, 2016: Michele Antonelli Appointed President Of Stallergenes Sas & Executive VP Head Of Europe & Row
Feb 01, 2016: Stallergenes Greer Announces Resumption Of Manufacturing At Its Antony Plant
Feb 01, 2016: Tibor Nemes Appointed Global Head of Technical Operations : Stallergenes Greer
Dec 07, 2015: Stallergenes Greer PLC: Recall of Allergy Immunotherapy Products
Dec 02, 2015: Temporary Suspension Of Manufacturing At Stallergenes Antony Plant

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table Of Contents

Stallergenes SAS (GENP) - Financial and Strategic SWOT Analysis Review
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Section 1 - About the Company 6
Stallergenes SAS - Key Facts 6
Stallergenes SAS - Key Employees 7
Stallergenes SAS - Key Employee Biographies 8
Stallergenes SAS - Major Products and Services 9
Stallergenes SAS - Pharmaceutical Pipeline Products Data 10
Stallergenes SAS, Pipeline Products by Therapy Area 10
Stallergenes SAS, Pipeline Products by Development Phase 11
Stallergenes SAS - History 13
Stallergenes SAS - Locations And Subsidiaries 17
Head Office 17
Other Locations and Subsidiaries 17
Section 2 - Company Analysis 18
Stallergenes SAS - Business Description 18
Stallergenes SAS - Corporate Strategy 19
Stallergenes SAS - SWOT Analysis 20
SWOT Analysis - Overview 20
Stallergenes SAS - Strengths 20
Strength - Portfolio of Allergen Immunotherapy Products 20
Strength - Revenue Driven by Strong Performance of All Administration Routes 20
Strength - Strong In-house Research Capabilities 20
Stallergenes SAS - Weaknesses 21
Weakness - Product Recall 21
Stallergenes SAS - Opportunities 22
Opportunity - Product Pipeline 22
Opportunity - Business Initiatives 22
Opportunity - Market Potential for Treatments for Allergic Rhinitis 22
Stallergenes SAS - Threats 23
Threat - Cost Containment Pressures 23
Threat - Uncertain RandD Outcomes 23
Threat - Intense Competition 23
Stallergenes SAS - Key Competitors 24
Section 3 - Company Financial Ratios 25
Financial Ratios - Capital Market Ratios 25
Financial Ratios - Annual Ratios 26
Performance Chart 28
Financial Performance 28
Financial Ratios - Interim Ratios 29
Financial Ratios - Ratio Charts 30
Section 4 - Company's Lifesciences Financial Deals and Alliances 31
Stallergenes SAS, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 31
Stallergenes SAS, Pharmaceuticals and Healthcare, Deals By Type, 2010 to YTD 2016 32
Stallergenes SAS, Recent Deals Summary 33
Section 5 - Company's Recent Developments 34
Feb 10, 2016: Michele Antonelli Appointed President Of Stallergenes Sas and Executive VP Head Of Europe and Row 34
Feb 01, 2016: Tibor Nemes Appointed Global Head of Technical Operations : Stallergenes Greer 35
Feb 01, 2016: Stallergenes Greer Announces Resumption Of Manufacturing At Its Antony Plant 36
Dec 07, 2015: Stallergenes Greer PLC: Recall of Allergy Immunotherapy Products 37
Dec 02, 2015: Temporary Suspension Of Manufacturing At Stallergenes Antony Plant 38
Jul 22, 2015: Stallergenes : Strong Revenue Growth In H1 2015 Exceeding Targets 39
Apr 21, 2015: Strong Sales Growth In Q1 2015 (up 7.5%) Exceeding Targets 40
Mar 03, 2015: 2.5% growth in net sales and EBITA outperformed 2014 targets 41
Section 6 - Appendix 43
Methodology 43
Ratio Definitions 43
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Stallergenes SAS, Key Facts 6
Stallergenes SAS, Key Employees 7
Stallergenes SAS, Key Employee Biographies 8
Stallergenes SAS, Major Products and Services 9
Stallergenes SAS, Number of Pipeline Products by Therapy Area 10
Stallergenes SAS, Number of Pipeline Products by Development Stage 11
Stallergenes SAS, Pipeline Products By Therapy Area and Development Phase 12
Stallergenes SAS, History 13
Stallergenes SAS, Subsidiaries 17
Stallergenes SAS, Key Competitors 24
Stallergenes SAS, Ratios based on current share price 25
Stallergenes SAS, Annual Ratios 26
Stallergenes SAS, Interim Ratios 29
Stallergenes SAS, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 31
Stallergenes SAS, Pharmaceuticals and Healthcare, Deals By Type, 2010 to YTD 2016 32
Stallergenes SAS, Recent Deals Summary 33
Currency Codes 43
Capital Market Ratios 43
Equity Ratios 44
Profitability Ratios 44
Cost Ratios 45
Liquidity Ratios 45
Leverage Ratios 46
Efficiency Ratios 46

List of Figures
Stallergenes SAS, Pipeline Products by Therapy Area 10
Stallergenes SAS, Pipeline Products by Development Phase 11
Stallergenes SAS, Performance Chart (2010 - 2014) 28
Stallergenes SAS, Ratio Charts 30
Stallergenes SAS, Pharmaceuticals and Healthcare, Deals By Year, 2010 to YTD 2016 31
Stallergenes SAS, Pharmaceuticals and Healthcare, Deals by Type, 2010 to YTD 2016 32

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.